Russia Registers Carnivac-Cov, World's 1st Covid-19 Vaccine for Animals
Published On Apr 01, 2021 12:00 AM By Yamini Sharma
According to Rosselkhoznadzor, The Federal Service for Veterinary and Phytosanitary of Russia, the country has registered the world's first animal vaccine against Covid-19. As per reports, the immunity lasts for six months after the vaccination. However, the developers of the Covid-19 dose are continuing their analysis on the same. Developed by a unit of Rosselkhoznadzor, the vaccine has been named Carnivac-Cov.
You May Also Check: Covid-19 Health Insurance
Konstantin Savenkov, Deputy Head, Rosselkhoznadzor informed that the clinical trials of Carnivac-Cov were conducted in October 2020. The clinical trials for the Covid-19 vaccine for animals included cats, dogs, foxes, minks, Arctic foxes, and other animals. Furthermore, he highlighted that Carnivac-Cov is the world's first and only product for preventing coronavirus in animals. Savenkov furthermore informed that the trial results showcase that the vaccine is harmless as well as highly immunogenic since all the vaccinated animals developed antibodies to the novel coronavirus in 100% of cases.
It must be noted that the mass production of the Covid-19 vaccine is likely to start as early as last month. Moreover, Russian scientists suggest that the use of Carnivac-Cov can prevent the development of virus mutations.
At present, Russia already has three Covid-19 vaccines for humans, Sputnik V being one of the most popular vaccines. EpiVacCorona and CoviVac have also received emergency approval.
As of now, Russia has 2,80,073 active cases of Covid-19.
Sources claim that private companies as well as animals-breeding facilities from the US, Austria, Canada, Singapore, Poland and Greece have expressed interest in Carnivac-Cov.
You May Also Like To Read:
Coronavirus Vaccine: What You Can And Cannot Do After Getting Vaccinated?
How Coronavirus Vaccine Trials Work?
Disclaimer: This article is issued in the general public interest and meant for general information purposes only. Readers are advised not to rely on the contents of the article as conclusive in nature and should research further or consult an expert in this regard.